Zhejiang East-Asia Pharmaceutical (605177.SH): Ipasit tablets obtained the drug registration certificate.
East Asia Pharmaceutical (605177.SH) announced that the company has recently received the "Drug Registration Certificate" for Ipatasertib tablets issued by the National Medical Products Administration. Ipatasertib is used to prevent, improve and treat peripheral nerve disorders associated with diabetes, such as numbness and pain.
Zhejiang East-Asia Pharmaceutical (605177.SH) released an announcement that the company recently received the "Drug Registration Certificate" for Yipasita tablets approved and issued by the National Medical Products Administration. Yipasita is used to prevent, improve, and treat peripheral neuropathy complications associated with diabetes, such as numbness and pain.
Related Articles
ETS GROUP (08031) issues 59.12 million shares based on general mandate.
On June 23, TENFU (06868) spent HK$7,880 to buy back 3,000 shares.
Changchun FAWAY Group Automobile Components (600742.SH) has won the bid for the exterior project of a new energy brand customer, with an estimated total sales amount of 704 million yuan.
ETS GROUP (08031) issues 59.12 million shares based on general mandate.
On June 23, TENFU (06868) spent HK$7,880 to buy back 3,000 shares.
Changchun FAWAY Group Automobile Components (600742.SH) has won the bid for the exterior project of a new energy brand customer, with an estimated total sales amount of 704 million yuan.
RECOMMEND
